Alerts

We have updated the information about these shortages with new details about affected products and a link to an additional resource for health professionals.

A warning about serious kidney damage has been added to the prescribing information for all oral anticoagulants in Australia.

The TGA is warning consumers against taking EVE branded products that contain allylisopropylacetylurea (apronal) as they pose a significant health risk and are prohibited from sale, supply or use in Australia.

The TGA has detected fake semaglutide, also known as Ozempic, being illegally imported into Australia.

The TGA is aware of a shortage of all hydrocortisone tablet strengths due to manufacturing issues. We are working with the supplier Alphapharm Pty Ltd to manage the impact.

A safety warning has been added to a class of medicines called Janus Kinase inhibitors used for chronic inflammatory conditions.

We continue to monitor antibiotic medicines in shortage and are seeking and prioritising applications for overseas alternatives to assist with supply.

Users may experience extended periods of signal loss and during this time they won’t receive high or low glucose alarms.

Medtronic Australasia is informing customers about the serious risk of valve infolding for EvolutePRO+ 34mm Transcatheter Aortic Valve (TAV), item code - EVPROPLUS-34US.

To help manage the shortage of the antibiotic phenoxymethylpenicillin (Penicillin V), we have made a Serious Scarcity Substitution Instrument (SSSI).

BioCeuticals is recalling one Batch 220380 (exp 02/2024) of Ultra Potent-C Chewable (60s) (AUST L 208690) following a consumer report of a metal fragment found in one tablet.

A 12-month shelf-life extension is now in place for all batches with an original expiry date from January 2022 to March 2025.

Read updated information on nitrosamine impurities, the TGA response and requirements for medicine sponsors and manufacturers.

As the shortage of Coumadin 5mg tablets is expected to continue, the TGA has made a Serious Scarcity Substitution Instrument to assist patients to access their medicine from their pharmacist without delay or interruption to treatment.

Information about the shortage of some antibiotics, including amoxicillin and metronidazole medicines

The TGA is aware of several warfarin product shortages due to manufacturing issues.

The TGA has decided to cancel the registration of pholcodine-containing medicines and is recalling them from pharmacies.

Church and Dwight are recalling two batches of Curash Nappy Rash Cream, following reports of adverse reactions

There remains an increased global demand for semaglutide products which is impacting availability and certainty of supply of Ozempic (semaglutide) in Australia until early 2023.

Boehringer Ingelheim (BI) has advised the TGA of a shortage of tenecteplase (Metalyse) injection that is predicted to extend over the next 18 months.

Update - Suspended breast implant devices now cancelled

Philips has advised that corrected pads will be shipped in early 2023 to customers affected by the problem.

The shortages list of antibiotics has been updated.

Recall of Glute Master -Maxx Products

Joint statement on the Ozempic (semaglutide) shortage and prioritisation for people with type 2 diabetes.